Please assess the completion status of the following clinical trial:

Trial Title: Community-Acquired Pneumonia : Evaluation of Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patients affiliated to social security scheme~* Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to the trial~* Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the following: cough, purulent sputum, chest pain and dyspnea~* Focal shadowing/infiltrate on chest X-ray or CT-scan~* Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital admission~* Study drug infusion initiated no longer than 24 hours post first severity criterion~* Severity defined by at least one of the following:~  * Pneumonia Severity Index (PSI) \> 130 (Fine class V)~ * Patient placed on mechanical ventilation (invasive or not) for acute respiratory failure, with a PEEP level of 5 cm of water or more~ * Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a P/F ratio less than 300~ * Patient treated by oxygen therapy with a partial rebreathing-mask with a reservoir bag, provided that the PaO2 is less than (cf. table):~Oxygen flow (L/min) 6 7 8 9 10 or more PaO2 (mmHg) less than 180 210 240 270 300~* Patient already treated by antibiotics (at least one dose since admission to hospital)~* Informed consent signed by the patient, its relatives or emergency procedure~On the sub-group of patients included with COVID19 :~* Diagnosis of COVID19 either as certain (PCR) or probable (evocative clinical and radiological features AND epidemic context AND absence of other microbiological documentation).~* Study drug infusion initiated no longer than 24 hours post first severity criterion ; in case of transfer from another hospital, this period will be prolonged to 48 hours~* Patient receiving the best available treatment as define by up-to-date scientific knowledge~Exclusion Criteria:~* Patient treated by vasopressors for septic shock at the time of inclusion~* Clinical history suggesting of aspiration of gastric content~* Patient treated by invasive mechanical ventilation within 14 days before current hospital admission~* Patient treated by antibiotics for a respiratory infection for more than seven days at the admission to the hospital (except if a pathogen resistant to this antibiotics is isolated)~* History of cystic fibrosis~* Post-obstructive pneumonia~* Patients in which rapid PCR-test is positive for flu~* Active tuberculosis or fungal infection~* Active viral hepatitis or active infection with herpes viruses~* Myelosuppression~* Decision of withholding mechanical ventilation or endotracheal intubation~* Hypersensitivity to corticosteroids~* Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for any reason~* Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more than 30 days~* Patient already enrolled in another drug trial with mortality as an end-point. If the patient is already participating in another therapeutic trial with a different endpoint, the investigator must verify that inclusion in CAPE COD can not prejudice it.~* Pregnant or breastfeeding woman~* Patient on judicial protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone (Type: EXPERIMENTAL): Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
- Placebo (Type: PLACEBO_COMPARATOR): Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)

Based on this trial design, predict the completion outcome and termination type (if applicable).